

New Sartorius Stedim BioOutsource Microsite Goes Live Cellca's Cell Line and Upstream Process Development Services Now Integrated

Goettingen, GER | Glasgow, UK – June 14, 2016: Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, announced that its subsidiary BioOutsource launched an updated website to spotlight Sartorius Stedim Cellca's cell line and upstream process development services for the biopharmaceutical industry. The new microsite features insights into the technology and development services of Cellca most recently acquired by SSB. The availability of both subsidiaries' unique range of integrated services will support biopharma companies to rapidly and cost-effectively develop their biologics and biosimilars.

The new microsite divides into four easy-to-navigate sections that explain Cellca's unique CHO Expression Platform which comprises of Expression Vector, Host Cell Line, CHO Media System and Upstream Process Design. This structure gives a simple overview of the technical details and time-saving benefits of this robust, scalable expression platform for individual applications.

Cellca's cell line and upstream process development services complement BioOutsource's broad range of bioanalytical and biosafety testing, as well as pre-qualified biosimilar assays. As a result, scientists and potential customers can source all their needs for developing biologics and biosimilars from one trusted supplier. Additionally, as both Cellca and BioOutsource have been part of Sartorius Stedim Biotech since 2015, biopharma firms that need to commercialize their biologics will not only benefit from this niche expertise, but can also access Sartorius Stedim Biotech's extensive global upstream process development capabilities to accelerate the development timeline of their biologics and biosimilars.

Gerry MacKay, Managing Director of Sartorius Stedim BioOutsource, commented: "We're pleased to be launching our new microsite because it signals the availability of our unique integrated services. Developers of biologics and biosimilars can now go to our site to find out how to access a fully integrated pathway from cell line development and data characterization through to upstream process development. They can also discover how these services will support them to comply with regulatory standards for timely, cost-effective development of their biosimilars."

To find out about Cellca's cell line and upstream process development services, scientists should click this link to the new microsite:

www.biooutsource.com/cell-line-and-upstream-process-development/

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves.

Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech has a global reach. The company employs approx. 4,200 people, and in 2015 earned sales revenue of 884.3 million euros.

Contacts:

Dominic Grone; Group Corporate Communications,
Sartorius Corporate Administration GmbH, Goettingen, Germany,
Phone: +49. (0)551-308.3324 ; Fax +49. (0)551-308.3410
Email: dominic.grone@sartorius.com; www.sartorius-stedim.com

Gemma Fulton; Marketing Manager, Sartorius Stedim BioOutsource Ltd, Glasgow, United Kingdom
Phone: +44(0)141.946.4222 Fax +44(0)141.946.4552
E-mail: gemma.fulton@sartorius-stedim.com; www.biooutsource.com